New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 12, 2014
04:55 EDTPRGO, PRGO, QSII, QSII, PKI, PKI, AMAG, AMAG, AMBI, AMBI, LLY, LLY, WAT, WAT, CSII, CSII, BLUE, BLUELeerink to hold a conference
2014 Global Healthcare Conference is being held in New York on February 12-13.
News For PRGO;QSII;PKI;AMAG;AMBI;LLY;WAT;CSII;BLUE From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | all recent news | >>
July 23, 2015
08:48 EDTPRGOMylan, Teva lower after Stitching looks to thwart hostile deal
Subscribe for More Information
08:43 EDTLLYEli Lilly Alzheimer's data positive, says SunTrust
Subscribe for More Information
08:33 EDTPRGOMylan foundation says shareholders at risk of Teva takeover
Subscribe for More Information
07:43 EDTCSIICMS panel removes Cardiovascular Systems overhang, says Leerink
Leerink analyst Danielle Antalffy says the CMS Medicare Evidence Development & Coverage Advisory Committee panel on peripheral arterial disease removes a near-term overhang on shares of Cardiovascular Systems. The company should return to 20%-plus growth with both outpatient reimbursement and CMS panel risk now addressed, Antalffy tells investors in a research note. She keeps an Outperform rating on the stock with a $45 price target.
07:25 EDTAMAGAMAG affirms FY15 revenue view $395M-$430M, consensus $465.45M
Raises FY15 adjusted EBITDA guidance view to $210M-$225M from $200M-$220M.
07:23 EDTAMAGAMAG reports Q2 adjusted EPS $1.12, one estimate $1.13
Subscribe for More Information
06:48 EDTLLYEli Lilly up 5.5% after reporting Q2 results, raising FY15 guidance
06:37 EDTLLYEli Lilly expands San Diego biotechnology center
Subscribe for More Information
06:33 EDTLLYEli Lilly raises FY15 EPS view to $3.20-$3.30 from $3.10-$3.20, consensus $3.18
Narrows FY15 revenue guidance to $19.7B-$20B from $19.5B-$20B, consensus $19.8B.
06:30 EDTLLYEli Lilly reports Q2 adjusted EPS 90c, consensus 74c
Subscribe for More Information
05:28 EDTQSIIQuality Systems reports Q1 non-GAAP EPS 16c, consensus 15c
Subscribe for More Information
July 22, 2015
16:10 EDTAMAGAMAG acquires option for rights to Velo Bio's digoxin immune fab
Subscribe for More Information
15:26 EDTLLYNotable companies reporting before tomorrow's open
Subscribe for More Information
10:59 EDTLLYBiogen drops after reporting data on Alzheimer's drug
The shares of Biogen (BIIB) are falling after the company released data on its Alzheimer's treatment candidate, aducanumab. Peer Eli Lilly (LLY) also reported data this morning on its own experimental Alzheimer's drug, solanezumab. BIOGEN: Biogen's data "does not inspire confidence," Piper analyst Joshua Schimmer wrote in a note to investors today. The 6 mg dose of the drug performed similarly to the 1mg dose, and was barely better than the placebo, the analyst stated. The cognitive and functional performance of the patients who took the 6 mg dose did not improve by a statistically significant amount, while the results of patients taking the other doses were "noisy,"Schimmer stated. Additionally, indications of excess fluid in the brain was observed in a significant number of patients, representing an additional problem for the treatment, the analyst believes. The data "is far from inspiring confidence" and makes the outlook for aducanumab "more speculative than ever," Schimmer contended. LILLY: Also this morning, Eli Lilly presented results from a pre-specified secondary analysis of several Phase 3 studies at the Alzheimer's Association International Conference. According to the company, the results suggest the treatment effect of solanezumab was preserved within a pre-specified amount in patients with mild Alzheimer's disease who received solanezumab earlier in the disease compared to patients who began treatment at a later point. Treatment differences in cognition and function between early-start and delayed-start groups at the end of the placebo-controlled period were preserved at the primary time point of 108 weeks within a pre-defined margin. Treatment differences in cognition and function between early-start and delayed-start groups at the end of the placebo-controlled period were also preserved at an additional time point of 132 weeks within a pre-defined margin.The differences at 108 weeks and at at 132 weeks remained statistically significant, the company said. PRICE ACTION: In morning trading, Biogen fell 3% to $397.43 while Eli Lilly shares rose 0.6% to $86.11.
10:06 EDTPRGOAbbott CEO says supportive of Mylan pursuit of Perrigo
Subscribe for More Information
10:05 EDTLLYEli Lilly gaps down, retraces, levels to watch
Subscribe for More Information
08:40 EDTLLYEli Lilly July weekly volatility elevated into Q2 and Alzheimer's drug data
Subscribe for More Information
07:18 EDTLLYEli Lilly drops 3% to $83 after reporting Alzheimer's drug data
Subscribe for More Information
07:14 EDTPRGOPerrigo agrees to acquire Yokebe
Subscribe for More Information
07:06 EDTLLYEli Lilly's solanezumab for Alzheimer's supports 'delayed-start' use
Subscribe for More Information
1 | 2 | 3 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use